Press Releases and Statements Read our latest company news and announcements Image Press Releases Filter and Search Filter by year - Any -20242023202220212020 Search 49 press releases Image September 10, 2024 LAKE OSWEGO, Oregon, USA Press Release BIOTRONIK Neuro Launches BioVantage™ Remote Care Review BIOTRONIK Neuro today announced an entirely new service option for Prospera™ patients, called BioVantage™. This expanded service option complements Prospera's daily remote monitoring by providing patients a remote, monthly check-in with an experienced spinal cord stimulation (SCS) specialist from BIOTRONIK Neuro’s Embrace One™ Care Team. The goal is to enhance patient therapy education and support, promoting not just optimal pain relief but also consistent progress toward the treatment plan. Ultimately, BioVantage aims to prolong patient engagement and compliance. Remote patient management has Image August 22, 2024 BUELACH, Switzerland Press Release BIOTRONIK Launches FlowGuide and Guidion Short, the Next Generation of Guide Extension Catheters BIOTRONIK today announces the launch of the latest innovations in guide extension catheters: FlowGuide and Guidion Short. These new devices have been developed to offer enhanced support and to facilitate the delivery of devices during complex vascular interventions. The catheters introduce key elements, such as perfusion holes in the distal shaft of the FlowGuide catheter, and a transradial access and trapping friendly design for both new products. Through our collaboration with IMDS, the FlowGuide and Guidion Short catheters expand BIOTRONIK's portfolio of high-performance devices dedicated Image July 11, 2024 MONTREAL, Canada Press Release Amvia Sky Launched in Canada, the World’s First Pacemaker Approved for LBBAP* Dr. Fadi Mansour performed the first Canadian implant of BIOTRONIK’s newest pacemaker and CRT-P generation earlier this year at the Centre Hospitalier de l'Université de Montréal. The patient received an Amvia Sky HF-T QP triple chamber pacemaker device. The first implant follows the full market release of BIOTRONIK’s newest family of pacemaker and CRT-P devices, featuring patient-centric technologies for better patient care and simplified workflows. “The Amvia Sky HF-T QP offers a significant number of advanced features, making it the most complete CRT-P on the market including streamlined Image July 1, 2024 BUELACH, SWITZERLAND Press Release BIOTRONIK Introduces Expanded Maximum Diameter Dimensions for Orsiro Mission DES BIOTRONIK is pleased to announce the availability of an expanded Maximum Allowed Diameters (MAD) range for the Orsiro® Mission Drug Eluting Stent (DES). Diameters 2.25mm to 3.00mm of the Orsiro Mission DES can now be extended up to 4.0mm, while diameters 3.5mm and 4.0mm can reach up to 5.0mm. This new MAD expansion follows the approvals from CE, FDA, and Health Canada obtained in the past months. This update reflects a global effort for the Orsiro Mission stent technology to match contemporary Percutaneous Coronary Intervention (PCI), enabling practitioners to optimize vessel apposition and Image May 30, 2024 BUELACH, SWITZERLAND Press Release One-Year BIONETIC-I Study Results Show Safety and Effectiveness of Iliac Artery Treatment With BIOTRONIK’s Dynetic-35 Cobalt Chromium Balloon-Expandable Stent System BIOTRONIK announced the presentation of the 12-month results from the BIONETIC-I study this week at LINC 2024. The prospective, international, multicenter single-arm observational study evaluated the treatment of de novo, restenotic or occluded iliac lesions in 160 patients with Rutherford Class 2-6 peripheral artery disease using the Dynetic ®-35 cobalt chromium balloon-expandable stent system. At baseline, 12.5% of enrolled patients had critical limb ischemia, 90% had calcified lesions (30.7% severe calcification), and there was an average of 85.5% stenosis in the target lesion. The primary Image May 17, 2024 BUELACH, SWITZERLAND Press Release BIOMAG-I Two-Year Study Results Confirm Excellent Safety and Efficacy Profile for Freesolve, BIOTRONIK’s Newest Resorbable Magnesium Scaffold Innovation New two-year follow-up data from the BIOMAG-I first-in-human trial confirms a reliable and predictable long-term safety profile for Freesolve™, the third-generation resorbable magnesium scaffold (RMS), establishing it as a true alternative to contemporary drug-eluting stents (DES). The results were presented by Prof. Dr. Michael Haude at the EuroPCR 2024 conference yesterday in Paris. At the 24-month follow-up, the incidence of target lesion failure (TLF) was 3.5% alongside a corresponding 3.5% incidence of target lesion revascularization (TLR) compares favorably with various second-generation Image May 13, 2024 BUELACH, SWITZERLAND Press Release New-Gen Resorbable Magnesium Scaffold Freesolve Enters BIOMAG-II Randomized Controlled Trial (RCT) BIOTRONIK announced today the enrollment of the first patient in the BIOMAG-II trial aiming to evaluate the safety and clinical performance of its new-generation resorbable magnesium scaffold (RMS), Freesolve™, compared to a contemporary drug-eluting stent (DES). "We are delighted to enroll the first patient in the BIOMAG-II trial, which may play a critical role in helping establish resorbable metallic scaffolds as part of clinical practice in the future and I am particularly encouraged by the implantation results of the Freesolve resorbable magnesium scaffold," said Dr. Juan F. Iglesias, HUG Image April 22, 2024 BERLIN, Germany Press Release BIOTRONIK and Texray Establish Collaboration to Distribute Texray’s Innovative Radiation Protection Products BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and endovascular solutions, proudly announces a multinational distribution partnership with Texray, the pioneering developer of a groundbreaking radiation protection textile. In this collaboration BIOTRONIK will distribute Texray's head and neck protectors starting in selected European and Middle Eastern countries. Both partners aim to raise awareness about the critical importance of radiation protection for healthcare professionals, who serve in environments where radiation exposure is an inherent Image November 27, 2023 BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with Image November 9, 2023 Statement Recent Acutus Stock Market Announcement On November 8, 2023, Acutus Medical announced they will immediately begin winding down manufacturing and distribution of the AcQMap 3D Mapping System, the AcQMap/SentiCath 3D Mapping Catheter, the AlCath Force Catheters, the Qubic Force, the AcQGuide/Adnovo Max 2.0 steerable sheath, and associated accessories. According to the company statement this is driven by challenges in the current financing environment. BIOTRONIK, as the distribution partner of Acutus in many countries around the world, deeply regrets this decision. BIOTRONIK had not been informed in advance of this development. We will Image October 5, 2023 LAKE OSWEGO, Oregon, USA Press Release Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ spinal cord stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in Image September 14, 2023 COPENHAGEN, Denmark Press Release BIOLUX P-III BENELUX All-Comers Registry Demonstrates Safety and Efficacy of BIOTRONIK’s Drug-Coated Balloon in Isolated Popliteal Lesions at 24 Months BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry, presented by Principal Investigator Prof. Frank Vermassen at CIRSE 2023 in Copenhagen, Denmark. 1 The prospective, international, multicenter post-market registry evaluated the safety and efficacy of the Passeo ®-18 Lux ® drug-coated balloon (DCB) catheter in isolated popliteal artery lesions. This indication is considered a difficult vessel bed to treat due to its biomechanical constraints that usually preclude the placement of stents. BIOLUX P-III BENELUX registry enrolled 99 patients in Belgium, the Pagination Current page 1 Pagina 2 Pagina 3 Pagina 4 Pagina 5 Next page Next › Subscribe to Our News JavaScript moet ingeschakeld zijn om dit formulier te kunnen gebruiken. Your Name Your Email Subject Message *Fields are mandatory. Latest Blog Posts Show all blog articles Image January 31, 2024 Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024 Image February 14, 2024 Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits Image March 7, 2024 Blog Improving Cardiovascular Health This International Women’s Day Press Contact Corporate Public Relations & Communications press@biotronik.com +49 (0) 30 68905 1414 Get in contact
Image September 10, 2024 LAKE OSWEGO, Oregon, USA Press Release BIOTRONIK Neuro Launches BioVantage™ Remote Care Review BIOTRONIK Neuro today announced an entirely new service option for Prospera™ patients, called BioVantage™. This expanded service option complements Prospera's daily remote monitoring by providing patients a remote, monthly check-in with an experienced spinal cord stimulation (SCS) specialist from BIOTRONIK Neuro’s Embrace One™ Care Team. The goal is to enhance patient therapy education and support, promoting not just optimal pain relief but also consistent progress toward the treatment plan. Ultimately, BioVantage aims to prolong patient engagement and compliance. Remote patient management has
Image September 10, 2024 LAKE OSWEGO, Oregon, USA Press Release BIOTRONIK Neuro Launches BioVantage™ Remote Care Review BIOTRONIK Neuro today announced an entirely new service option for Prospera™ patients, called BioVantage™. This expanded service option complements Prospera's daily remote monitoring by providing patients a remote, monthly check-in with an experienced spinal cord stimulation (SCS) specialist from BIOTRONIK Neuro’s Embrace One™ Care Team. The goal is to enhance patient therapy education and support, promoting not just optimal pain relief but also consistent progress toward the treatment plan. Ultimately, BioVantage aims to prolong patient engagement and compliance. Remote patient management has
Image August 22, 2024 BUELACH, Switzerland Press Release BIOTRONIK Launches FlowGuide and Guidion Short, the Next Generation of Guide Extension Catheters BIOTRONIK today announces the launch of the latest innovations in guide extension catheters: FlowGuide and Guidion Short. These new devices have been developed to offer enhanced support and to facilitate the delivery of devices during complex vascular interventions. The catheters introduce key elements, such as perfusion holes in the distal shaft of the FlowGuide catheter, and a transradial access and trapping friendly design for both new products. Through our collaboration with IMDS, the FlowGuide and Guidion Short catheters expand BIOTRONIK's portfolio of high-performance devices dedicated
Image August 22, 2024 BUELACH, Switzerland Press Release BIOTRONIK Launches FlowGuide and Guidion Short, the Next Generation of Guide Extension Catheters BIOTRONIK today announces the launch of the latest innovations in guide extension catheters: FlowGuide and Guidion Short. These new devices have been developed to offer enhanced support and to facilitate the delivery of devices during complex vascular interventions. The catheters introduce key elements, such as perfusion holes in the distal shaft of the FlowGuide catheter, and a transradial access and trapping friendly design for both new products. Through our collaboration with IMDS, the FlowGuide and Guidion Short catheters expand BIOTRONIK's portfolio of high-performance devices dedicated
Image July 11, 2024 MONTREAL, Canada Press Release Amvia Sky Launched in Canada, the World’s First Pacemaker Approved for LBBAP* Dr. Fadi Mansour performed the first Canadian implant of BIOTRONIK’s newest pacemaker and CRT-P generation earlier this year at the Centre Hospitalier de l'Université de Montréal. The patient received an Amvia Sky HF-T QP triple chamber pacemaker device. The first implant follows the full market release of BIOTRONIK’s newest family of pacemaker and CRT-P devices, featuring patient-centric technologies for better patient care and simplified workflows. “The Amvia Sky HF-T QP offers a significant number of advanced features, making it the most complete CRT-P on the market including streamlined
Image July 11, 2024 MONTREAL, Canada Press Release Amvia Sky Launched in Canada, the World’s First Pacemaker Approved for LBBAP* Dr. Fadi Mansour performed the first Canadian implant of BIOTRONIK’s newest pacemaker and CRT-P generation earlier this year at the Centre Hospitalier de l'Université de Montréal. The patient received an Amvia Sky HF-T QP triple chamber pacemaker device. The first implant follows the full market release of BIOTRONIK’s newest family of pacemaker and CRT-P devices, featuring patient-centric technologies for better patient care and simplified workflows. “The Amvia Sky HF-T QP offers a significant number of advanced features, making it the most complete CRT-P on the market including streamlined
Image July 1, 2024 BUELACH, SWITZERLAND Press Release BIOTRONIK Introduces Expanded Maximum Diameter Dimensions for Orsiro Mission DES BIOTRONIK is pleased to announce the availability of an expanded Maximum Allowed Diameters (MAD) range for the Orsiro® Mission Drug Eluting Stent (DES). Diameters 2.25mm to 3.00mm of the Orsiro Mission DES can now be extended up to 4.0mm, while diameters 3.5mm and 4.0mm can reach up to 5.0mm. This new MAD expansion follows the approvals from CE, FDA, and Health Canada obtained in the past months. This update reflects a global effort for the Orsiro Mission stent technology to match contemporary Percutaneous Coronary Intervention (PCI), enabling practitioners to optimize vessel apposition and
Image July 1, 2024 BUELACH, SWITZERLAND Press Release BIOTRONIK Introduces Expanded Maximum Diameter Dimensions for Orsiro Mission DES BIOTRONIK is pleased to announce the availability of an expanded Maximum Allowed Diameters (MAD) range for the Orsiro® Mission Drug Eluting Stent (DES). Diameters 2.25mm to 3.00mm of the Orsiro Mission DES can now be extended up to 4.0mm, while diameters 3.5mm and 4.0mm can reach up to 5.0mm. This new MAD expansion follows the approvals from CE, FDA, and Health Canada obtained in the past months. This update reflects a global effort for the Orsiro Mission stent technology to match contemporary Percutaneous Coronary Intervention (PCI), enabling practitioners to optimize vessel apposition and
Image May 30, 2024 BUELACH, SWITZERLAND Press Release One-Year BIONETIC-I Study Results Show Safety and Effectiveness of Iliac Artery Treatment With BIOTRONIK’s Dynetic-35 Cobalt Chromium Balloon-Expandable Stent System BIOTRONIK announced the presentation of the 12-month results from the BIONETIC-I study this week at LINC 2024. The prospective, international, multicenter single-arm observational study evaluated the treatment of de novo, restenotic or occluded iliac lesions in 160 patients with Rutherford Class 2-6 peripheral artery disease using the Dynetic ®-35 cobalt chromium balloon-expandable stent system. At baseline, 12.5% of enrolled patients had critical limb ischemia, 90% had calcified lesions (30.7% severe calcification), and there was an average of 85.5% stenosis in the target lesion. The primary
Image May 30, 2024 BUELACH, SWITZERLAND Press Release One-Year BIONETIC-I Study Results Show Safety and Effectiveness of Iliac Artery Treatment With BIOTRONIK’s Dynetic-35 Cobalt Chromium Balloon-Expandable Stent System BIOTRONIK announced the presentation of the 12-month results from the BIONETIC-I study this week at LINC 2024. The prospective, international, multicenter single-arm observational study evaluated the treatment of de novo, restenotic or occluded iliac lesions in 160 patients with Rutherford Class 2-6 peripheral artery disease using the Dynetic ®-35 cobalt chromium balloon-expandable stent system. At baseline, 12.5% of enrolled patients had critical limb ischemia, 90% had calcified lesions (30.7% severe calcification), and there was an average of 85.5% stenosis in the target lesion. The primary
Image May 17, 2024 BUELACH, SWITZERLAND Press Release BIOMAG-I Two-Year Study Results Confirm Excellent Safety and Efficacy Profile for Freesolve, BIOTRONIK’s Newest Resorbable Magnesium Scaffold Innovation New two-year follow-up data from the BIOMAG-I first-in-human trial confirms a reliable and predictable long-term safety profile for Freesolve™, the third-generation resorbable magnesium scaffold (RMS), establishing it as a true alternative to contemporary drug-eluting stents (DES). The results were presented by Prof. Dr. Michael Haude at the EuroPCR 2024 conference yesterday in Paris. At the 24-month follow-up, the incidence of target lesion failure (TLF) was 3.5% alongside a corresponding 3.5% incidence of target lesion revascularization (TLR) compares favorably with various second-generation
Image May 17, 2024 BUELACH, SWITZERLAND Press Release BIOMAG-I Two-Year Study Results Confirm Excellent Safety and Efficacy Profile for Freesolve, BIOTRONIK’s Newest Resorbable Magnesium Scaffold Innovation New two-year follow-up data from the BIOMAG-I first-in-human trial confirms a reliable and predictable long-term safety profile for Freesolve™, the third-generation resorbable magnesium scaffold (RMS), establishing it as a true alternative to contemporary drug-eluting stents (DES). The results were presented by Prof. Dr. Michael Haude at the EuroPCR 2024 conference yesterday in Paris. At the 24-month follow-up, the incidence of target lesion failure (TLF) was 3.5% alongside a corresponding 3.5% incidence of target lesion revascularization (TLR) compares favorably with various second-generation
Image May 13, 2024 BUELACH, SWITZERLAND Press Release New-Gen Resorbable Magnesium Scaffold Freesolve Enters BIOMAG-II Randomized Controlled Trial (RCT) BIOTRONIK announced today the enrollment of the first patient in the BIOMAG-II trial aiming to evaluate the safety and clinical performance of its new-generation resorbable magnesium scaffold (RMS), Freesolve™, compared to a contemporary drug-eluting stent (DES). "We are delighted to enroll the first patient in the BIOMAG-II trial, which may play a critical role in helping establish resorbable metallic scaffolds as part of clinical practice in the future and I am particularly encouraged by the implantation results of the Freesolve resorbable magnesium scaffold," said Dr. Juan F. Iglesias, HUG
Image May 13, 2024 BUELACH, SWITZERLAND Press Release New-Gen Resorbable Magnesium Scaffold Freesolve Enters BIOMAG-II Randomized Controlled Trial (RCT) BIOTRONIK announced today the enrollment of the first patient in the BIOMAG-II trial aiming to evaluate the safety and clinical performance of its new-generation resorbable magnesium scaffold (RMS), Freesolve™, compared to a contemporary drug-eluting stent (DES). "We are delighted to enroll the first patient in the BIOMAG-II trial, which may play a critical role in helping establish resorbable metallic scaffolds as part of clinical practice in the future and I am particularly encouraged by the implantation results of the Freesolve resorbable magnesium scaffold," said Dr. Juan F. Iglesias, HUG
Image April 22, 2024 BERLIN, Germany Press Release BIOTRONIK and Texray Establish Collaboration to Distribute Texray’s Innovative Radiation Protection Products BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and endovascular solutions, proudly announces a multinational distribution partnership with Texray, the pioneering developer of a groundbreaking radiation protection textile. In this collaboration BIOTRONIK will distribute Texray's head and neck protectors starting in selected European and Middle Eastern countries. Both partners aim to raise awareness about the critical importance of radiation protection for healthcare professionals, who serve in environments where radiation exposure is an inherent
Image April 22, 2024 BERLIN, Germany Press Release BIOTRONIK and Texray Establish Collaboration to Distribute Texray’s Innovative Radiation Protection Products BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and endovascular solutions, proudly announces a multinational distribution partnership with Texray, the pioneering developer of a groundbreaking radiation protection textile. In this collaboration BIOTRONIK will distribute Texray's head and neck protectors starting in selected European and Middle Eastern countries. Both partners aim to raise awareness about the critical importance of radiation protection for healthcare professionals, who serve in environments where radiation exposure is an inherent
Image November 27, 2023 BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image November 27, 2023 BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image November 9, 2023 Statement Recent Acutus Stock Market Announcement On November 8, 2023, Acutus Medical announced they will immediately begin winding down manufacturing and distribution of the AcQMap 3D Mapping System, the AcQMap/SentiCath 3D Mapping Catheter, the AlCath Force Catheters, the Qubic Force, the AcQGuide/Adnovo Max 2.0 steerable sheath, and associated accessories. According to the company statement this is driven by challenges in the current financing environment. BIOTRONIK, as the distribution partner of Acutus in many countries around the world, deeply regrets this decision. BIOTRONIK had not been informed in advance of this development. We will
Image November 9, 2023 Statement Recent Acutus Stock Market Announcement On November 8, 2023, Acutus Medical announced they will immediately begin winding down manufacturing and distribution of the AcQMap 3D Mapping System, the AcQMap/SentiCath 3D Mapping Catheter, the AlCath Force Catheters, the Qubic Force, the AcQGuide/Adnovo Max 2.0 steerable sheath, and associated accessories. According to the company statement this is driven by challenges in the current financing environment. BIOTRONIK, as the distribution partner of Acutus in many countries around the world, deeply regrets this decision. BIOTRONIK had not been informed in advance of this development. We will
Image October 5, 2023 LAKE OSWEGO, Oregon, USA Press Release Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ spinal cord stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in
Image October 5, 2023 LAKE OSWEGO, Oregon, USA Press Release Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ spinal cord stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in
Image September 14, 2023 COPENHAGEN, Denmark Press Release BIOLUX P-III BENELUX All-Comers Registry Demonstrates Safety and Efficacy of BIOTRONIK’s Drug-Coated Balloon in Isolated Popliteal Lesions at 24 Months BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry, presented by Principal Investigator Prof. Frank Vermassen at CIRSE 2023 in Copenhagen, Denmark. 1 The prospective, international, multicenter post-market registry evaluated the safety and efficacy of the Passeo ®-18 Lux ® drug-coated balloon (DCB) catheter in isolated popliteal artery lesions. This indication is considered a difficult vessel bed to treat due to its biomechanical constraints that usually preclude the placement of stents. BIOLUX P-III BENELUX registry enrolled 99 patients in Belgium, the
Image September 14, 2023 COPENHAGEN, Denmark Press Release BIOLUX P-III BENELUX All-Comers Registry Demonstrates Safety and Efficacy of BIOTRONIK’s Drug-Coated Balloon in Isolated Popliteal Lesions at 24 Months BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry, presented by Principal Investigator Prof. Frank Vermassen at CIRSE 2023 in Copenhagen, Denmark. 1 The prospective, international, multicenter post-market registry evaluated the safety and efficacy of the Passeo ®-18 Lux ® drug-coated balloon (DCB) catheter in isolated popliteal artery lesions. This indication is considered a difficult vessel bed to treat due to its biomechanical constraints that usually preclude the placement of stents. BIOLUX P-III BENELUX registry enrolled 99 patients in Belgium, the
Image January 31, 2024 Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024
Image January 31, 2024 Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024
Image February 14, 2024 Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits
Image February 14, 2024 Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits